These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3334423)

  • 1. [Symposium on diagnosis and treatment of cancer. Recent progress. II. Treatment of cancer 2. Recent advance in immunotherapy].
    Urushizaki I
    Nihon Naika Gakkai Zasshi; 1987 Nov; 76(11):1663-8. PubMed ID: 3334423
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cytokines as immunotherapy in cancer].
    van der Schelling GP; Ijzermans JN; Marquet RL; Jeekel J
    Ned Tijdschr Geneeskd; 1992 Apr; 136(14):681-5. PubMed ID: 1373229
    [No Abstract]   [Full Text] [Related]  

  • 3. [The significance and outlook of cytokines in cancer therapy].
    Nihon Gan Chiryo Gakkai Shi; 1988 Apr; 23(4):907-15. PubMed ID: 3144574
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytokine gene-modified vaccines in the therapy of cancer.
    Bubenik J
    Pharmacol Ther; 1996; 69(1):1-14. PubMed ID: 8857300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological response modifiers: the new immunotherapy.
    Foon KA
    Cancer Res; 1989 Apr; 49(7):1621-39. PubMed ID: 2466558
    [No Abstract]   [Full Text] [Related]  

  • 6. The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2.
    Rosenberg SA
    Semin Oncol; 1986 Jun; 13(2):200-6. PubMed ID: 3520827
    [No Abstract]   [Full Text] [Related]  

  • 7. Interactions of cytokines in the host.
    Lundholm K
    Acta Chir Scand Suppl; 1989; 549():31-4. PubMed ID: 2648715
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunological approaches to the treatment of malignant disease.
    Guillou PJ
    J R Coll Surg Edinb; 1988 Feb; 33(1):2-8. PubMed ID: 2458468
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential impact of immunobiotechnology on cancer therapy.
    Guillou PJ
    Br J Surg; 1987 Aug; 74(8):705-10. PubMed ID: 2443206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Rosenberg SA
    Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
    [No Abstract]   [Full Text] [Related]  

  • 11. Symposium on diagnosis and treatment of cancer. Recent progress.
    Jpn J Med; 1988 Feb; 27(1):96-112. PubMed ID: 2452911
    [No Abstract]   [Full Text] [Related]  

  • 12. Current and new strategies in immunotherapy for superficial bladder cancer.
    Perabo FG; Müller SC
    Urology; 2004 Sep; 64(3):409-21. PubMed ID: 15351555
    [No Abstract]   [Full Text] [Related]  

  • 13. [Recombinant blood hormones in clinical practice].
    von dem Borne AE
    Ned Tijdschr Geneeskd; 1987 Nov; 131(46):2068-72. PubMed ID: 2446154
    [No Abstract]   [Full Text] [Related]  

  • 14. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.
    Rosenberg SA
    Ann Surg; 1988 Aug; 208(2):121-35. PubMed ID: 3041925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokines in tumour therapy.
    Hill AD; Redmond HP; Croke DT; Grace PA; Bouchier-Hayes D
    Br J Surg; 1992 Oct; 79(10):990-7. PubMed ID: 1384923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future perspectives for biological response modifiers: a viewpoint.
    Mihich E
    Semin Oncol; 1986 Jun; 13(2):234-54. PubMed ID: 2424090
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunomodulatory agents: the cytokines.
    Stein RC; Dalgleish AG
    Eur J Cancer; 1994; 30A(3):400-4. PubMed ID: 8204368
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.
    Yang SC; Fry KD; Grimm EA; Roth JA
    Arch Surg; 1990 Feb; 125(2):220-5. PubMed ID: 2137327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological response modifiers in renal cancer.
    Ackermann R
    Prog Clin Biol Res; 1988; 269():313-28. PubMed ID: 2455907
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo and in vitro activation of NK cytotoxicity with IL-2.
    Ibayashi Y; Tokuda Y; Saks ER; Sarna GP; Golub SH
    Prog Clin Biol Res; 1987; 244():275-85. PubMed ID: 3498954
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.